Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPGAP-B: Intraperitoneal Paclitaxel in Gastrointestinal Malignancies With Peritoneal Carcinomatosis
NCT07795749Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection in gastrointestinal malignancies, peritoneal carcinomatosis (PC), gastric cancer (GC), esophageal carcinoma, colorectal adenocarcinoma, sponsored by University of California, Irvine. Started Aug 2026; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
gastrointestinal malignanciesperitoneal carcinomatosis (PC)gastric cancer (GC)esophageal carcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07795749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795749.